M. Maccarrone, R. Maldonado, M. Casas, T. Henze and D. Centonze. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol. 10(4)443-55. PMID: 28276775
This article reviews the most important current (2017) data involving the eCB system in relation to human diseases, to reflect the present (based mainly on the most used prescription cannabinoid medicine, THC/CBD oromucosal spray) and potential future uses of cannabinoid-based therapy. It is noteworthy that THC/CBD oromucosal spray has been in clinical use for approximately five years in numerous countries world-wide for the management of multiple sclerosis (MS)-related moderate to severe resistant spasticity. Clinical trials have already confirmed its efficacy and tolerability. Other diseases in which different cannabinoids are currently being investigated include various pain states, Alzheimer's disease, Parkinson's disease, Huntington's disease and epilepsy.
C. Mannucci, M. Navarra, F. Calapai, E. Spagnolo, E. Busardò, R. Da Cas, F. Ippolito and G. Calapai. Neurological aspects of medical use of cannabidiol. CNS Neurol Disord Drug Targets PMID: 28412918
This was a review article on the potential role of Cannabidiol in Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis andcerebral ischemia were examined. The researchers have concluded that CBD can possibly produce beneficial effects in Parkinson's disease, Alzheimer's disease, multiple sclerosis patients as well as patients affected by refractory epilepsy.